The definitive merger agreement stipulates that GHO and Ampersand will purchase all outstanding shares of Avid.

This week, biologics CDMO Avid Bioservices revealed that it’s agreed to be acquired by funds managed by Ampersand and British ...

Aave (AAVE) sank toward $130, while four whales unstaked their positions from the Aave vaults and sent the tokens to ...

Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high ...

The merger agreement is valued at approximately $1.1 billion. Avid Bioservices, a biologics contract development and manufacturing organization (CDMO), announced on Nov. 6, 2024 that it has entered ...

GHO Capital Partners and Ampersand Capital Partners have agreed to acquire Avid Bioservices, a biologics contract development and manufacturing organization, in an all-cash transaction valued at ...

Avid Bioservices (CDMO) has agreed to be acquired by GHO Capital Partners and Ampersand Capital Partners through a cash deal that values the company at $1.1B. Read more here.

Avid Bioservices (CDMO), GHO Capital Partners LLP and Ampersand Capital Partners announced they have entered into a definitive merger agreement for Avid to be acquired by funds managed by GHO and ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avid Bioservices, Inc. (NASDAQ: CDMO) to ...

Of taxes and tariffs; the dealing begins; yelling at Yellin; Paul Singer not amused by Bloomberg report; and more!

RBC Capital downgraded Avid Bioservices (CDMO) to Sector Perform from Outperform with a price target of $12.50, up from $12, after the company ...

Ademi LLP is investigating Avid (NASDAQ: CDMO) for possible breaches of fiduciary duty and other violations of law in its transaction with GHO and Ampersand. Click here to learn how to join our ...